NCT03770637View on ClinicalTrials.gov

Glucagon Ready to Use (RTU) in Subjects With Hyperinsulinemic Hypoglycemia After Bariatric Surgery

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 10, 2019

Primary Completion Date

February 26, 2020

Study Completion Date

February 26, 2020

Conditions
Hyperinsulinemic Hypoglycemia
Interventions
DRUG

Glucagon RTU

Glucagon RTU is a sterile subcutaneous injectable non-aqueous solution formulation supplied in a vial and administered via syringe.

OTHER

Placebo

The placebo is a non-active version of Glucagon RTU formulation, containing the same solvent and excipients (i.e., vehicle).

Trial Locations (5)

21287

Johns Hopkins Hospital, Baltimore

27701

Duke Early Phase Clinical Research, Durham

55905

Mayo Clinic- Rochester, Rochester

80045

University of Colorado-Denver, Aurora

02215

Joslin Diabetes Center, Boston

Sponsors
All Listed Sponsors
lead

Xeris Pharmaceuticals

INDUSTRY